FAQ on Soligenix Inc.'s Heat-Stable Ricin Vaccine Development

What is RiVax®?

RiVax® is a heat-stable subunit protein vaccine developed by Soligenix Inc. to protect against ricin toxin exposure, incorporating ThermoVax® technology for stability without cold-chain storage.

Why is the development of a ricin vaccine important?

Ricin toxin is a potent biothreat, with even a minuscule dose being fatal within 48 to 72 hours, making the development of an effective vaccine critical for public safety and biodefense.

How does ThermoVax® technology benefit the RiVax® vaccine?

ThermoVax® technology allows the RiVax® vaccine to be heat-stable, eliminating the need for cold-chain storage, which is crucial for widespread distribution and use in various settings.

What stage of development is RiVax® currently in?

RiVax® has been shown to be safe in phase 1 studies in humans, with future steps including pivotal animal efficacy studies to further evaluate its effectiveness.

Who is developing the RiVax® vaccine?

Soligenix Inc. (NASDAQ: SNGX) is the biopharmaceutical company advancing the RiVax® vaccine, leveraging its proprietary ThermoVax® technology for development.

Where can I find more information about Soligenix and RiVax®?

More information about Soligenix and the RiVax® vaccine is available in the company’s newsroom at https://ibn.fm/SNGX and through InvestorWire at https://www.investorwire.com/.

What are the implications of a successful RiVax® vaccine?

A successful RiVax® vaccine would provide a critical tool in biodefense against ricin toxin, offering long-lasting immunity and addressing a significant public safety need with a heat-stable solution.

How does RiVax® compare to other vaccines or treatments for ricin exposure?

RiVax® is distinguished by its heat-stability due to ThermoVax® technology, making it more practical for distribution and storage compared to vaccines requiring cold-chain logistics.